✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Patent 7,396,841 protects PREVACID IV and is included in one NDA.
Protection for PREVACID IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has six patent family members in five countries.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,396,841
|Abstract:||An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.|
|Inventor(s):||Doen; Takayuki (Suita, JP), Nagao; Masao (Kashiba, JP), Asakawa; Naoki (Takatsuki, JP), Takechi; Nobuyuki (Osaka, JP)|
|Assignee:||Takeda Pharmaceutical Company Limited (Osaka, JP)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Formulation; Process; Use;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use||Submissiondate|
|Takeda Pharms Na||PREVACID IV||lansoprazole||INJECTABLE;INTRAVENOUS||021566-001||May 27, 2004||DISCN||Yes||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Patented / Exclusive Use||>Submissiondate|
Foreign Priority and PCT Information for Patent: 7,396,841
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Australia||7875501||See Plans and Pricing|
|Canada||2419067||See Plans and Pricing|
|European Patent Office||1310252||See Plans and Pricing|
|Japan||2002128675||See Plans and Pricing|
|Japan||4136340||See Plans and Pricing|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|